Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety Follow-up of Treatment With Remestemcel-L in Pediatric Patients Who Have Failed to Respond to Steroid Treatment for Acute GVHD

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02652130
Recruitment Status : Completed
First Posted : January 11, 2016
Last Update Posted : April 2, 2020
Sponsor:
Collaborator:
Quintiles, Inc.
Information provided by (Responsible Party):
Mesoblast, Ltd. ( Mesoblast, Inc. )

Brief Summary:
Ongoing safety assessment follow up to Protocol MSB-GVHD 001 of remestemcel-L treatment in pediatric subjects with acute Graft versus Host Disease (aGVHD), following allogeneic hematopoietic stem cell transplant (HSCT), that have failed to respond to treatment with systemic corticosteroid therapy.

Condition or disease Intervention/treatment Phase
Grade B Acute Graft Versus Host Disease Grade C Acute Graft Versus Host Disease Grade D Acute Graft Versus Host Disease Biological: Remestemcel-L Phase 3

Detailed Description:
This is a safety follow-up study through 180 days of remestemcel-L treatment in subjects who participated in MSB-GVHD001. This study will also explore duration of response over time. Subjects who participated in MSB-GVHD001 and received at least one dose of remestemcel-L as outlined in that protocol will be evaluated at baseline (Day 100) and at Days 120, 140, 160 and 180 for safety endpoints. Subjects who participated in Protocol MSB-GVHD001 and received the first 8 doses of remestemcel-L as outlined in that protocol will be evaluated at baseline (Day 100) and at Days 120, 140, 160 and 180.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 32 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Other
Official Title: Safety Follow-up Through 180 Days of Treatment With Remestemcel-L in Study MSB-GVHD001 in Pediatric Patients Who Have Failed to Respond to Steroid Treatment for Acute GVHD
Actual Study Start Date : October 28, 2015
Actual Primary Completion Date : June 15, 2018
Actual Study Completion Date : June 15, 2018


Arm Intervention/treatment
Experimental: Safety population
All subjects who participated in Protocol MSB-GVHD001 and received at least one remestemcel-L infusion in that protocol.
Biological: Remestemcel-L
No intervention given in GVHD002. It is a safety follow-up trial of Remestemcel-L treated subjects from GVHD001 trial




Primary Outcome Measures :
  1. Number of participants with adverse events [ Time Frame: 180 days ]
  2. Number of participants with serious adverse events [ Time Frame: 180 days ]
  3. Survival through Day 180 [ Time Frame: 180 days ]
  4. Number of participants with ectopic tissue formation [ Time Frame: 180 days ]

Secondary Outcome Measures :
  1. Survival at 180 days for participants who received the initial therapy through 28 days as outlined in Protocol MSB-GVHD001 [ Time Frame: 180 days ]
  2. GVHD activity by means of Quality of Life survey to investigational medicinal product (IMP) administered in MSBGVHD001 [ Time Frame: 180 days ]
  3. Corticosteroid use by participants able to taper by 50% at each time point. [ Time Frame: Up to 180 days ]
  4. Time to addition of any second-line GVHD treatment agent [ Time Frame: 180 days ]
  5. The number of days to GVHD flares [ Time Frame: 180 days ]
  6. The number of participants with chronic GVHD [ Time Frame: 180 days ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   2 Months to 17 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Patients are eligible for the study if all of the following criteria are met:

  • Subjects must have participated in gvhd001 and received at least one infusion of remestemcel L
  • Subject or subject's authorized representative must be capable of providing written informed consent. Assent, if applicable, must also be collected when required by the Institutional Review Board (IRB)/Ethics Committee (EC).
  • Female subjects of childbearing potential (≥ 10 years of age) must use a medically accepted method of contraception and must agree to continue use of this method for the duration of the study and for the follow-up time period. Acceptable methods of contraception include abstinence, barrier method with spermicide, intrauterine device (IUD), or steroidal contraceptive (oral, transdermal, implanted, and injected) in conjunction with a barrier method.
  • The subject must be willing and able to comply with study procedures, remain at the clinic as required during the study period, and return to the clinic for the follow-up evaluation as specified in this protocol.

Exclusion Criteria:

  • The investigator believes it to be in the best interest of the subject not to participate in the safety follow up study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02652130


Locations
Show Show 20 study locations
Sponsors and Collaborators
Mesoblast, Inc.
Quintiles, Inc.
Investigators
Layout table for investigator information
Study Director: Mahboob Rahman, MD Mesoblast, Inc.
Layout table for additonal information
Responsible Party: Mesoblast, Inc.
ClinicalTrials.gov Identifier: NCT02652130    
Other Study ID Numbers: MSB-GVHD002
First Posted: January 11, 2016    Key Record Dates
Last Update Posted: April 2, 2020
Last Verified: March 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Mesoblast, Ltd. ( Mesoblast, Inc. ):
GVHD, Graft versus Host Disease
Additional relevant MeSH terms:
Layout table for MeSH terms
Graft vs Host Disease
Immune System Diseases